RBC NOS: regulatory mechanisms and therapeutic aspects
Authors:
- Marijke GrauMGMarijke Grau
- Malte KelmMKMalte Kelm
- 1 July 2008
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 14 (7) , 314-322
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- Higher blood flow and circulating NO products offset high-altitude hypoxia among TibetansProceedings of the National Academy of Sciences, 2007
- S -nitrosohemoglobin deficiency: A mechanism for loss of physiological activity in banked bloodProceedings of the National Academy of Sciences, 2007
- Evolution of adverse changes in stored RBCsProceedings of the National Academy of Sciences, 2007
- S-Nitrosothiols signal hypoxia-mimetic vascular pathologyJournal of Clinical Investigation, 2007
- Arginase‐flotillin interaction brings arginase to red blood cell membraneFEBS Letters, 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Erythrocyte adhesiveness/aggregation: A novel biomarker for the detection of low-grade internal inflammation in individuals with atherothrombotic risk factors and proven vascular diseaseAmerican Heart Journal, 2005
- Membrane and raft association of reggie-1/flotillin-2: role of myristoylation, palmitoylation and oligomerization and induction of filopodia by overexpressionBiochemical Journal, 2004
- Partial purification of the Ca2+-Mg2+ ATPase activator from human erythrocytes: Its similarity to the activator of 3′:5′ — cyclic nucleotide phosphodiesteraseBiochemical and Biophysical Research Communications, 1977
- A functional acetylcholine receptor in the human erythrocyteBiochemical and Biophysical Research Communications, 1974